Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy
Section snippets
Conflict of interest
AZ has received honoraria from Shire, Pfizer and Genzyme.
JG has received travel support from Genzyme, Amicus, Actelion, Pfizer, Shire and Protalix.
JS has received travel grants from Shire, Pfizer and Genzyme.
References (17)
- et al.
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy
Blood
(2017) - et al.
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
Lancet
(2000) - et al.
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial
Lancet
(2015) - et al.
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
Blood
(2011) - et al.
Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase
Blood Cells Mol. Dis.
(2014) - et al.
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement
Blood
(2007) - et al.
Enzyme replacement therapy “drug holiday”: results from an unexpected shortage of an orphan drug supply in Australia
Blood Cells Mol. Dis.
(2011) - et al.
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1
Blood
(2010)
There are more references available in the full text version of this article.
Cited by (11)
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
2018, Blood Cells, Molecules, and DiseasesReal-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
2022, Journal of Clinical MedicineHematological manifestations and complications of Gaucher disease
2021, Expert Review of HematologyCurrent and emerging pharmacotherapy for Gaucher disease in pediatric populations
2021, Expert Opinion on PharmacotherapyA patient with Gaucher disease and plasma cell dyscrasia: Bidirectional impact
2020, Hematology (United States)Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
2020, Frontiers in Cell and Developmental Biology
© 2017 Elsevier Inc. All rights reserved.